Pulmatrix (PULM) Competitors $5.40 -0.56 (-9.40%) Closing price 04/4/2025 03:59 PM EasternExtended Trading$5.42 +0.02 (+0.46%) As of 04/4/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PULM vs. EDIT, TELO, CHRS, VXRT, OPTN, ANIX, ADVM, FATE, VOR, and BDTXShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Editas Medicine (EDIT), Telomir Pharmaceuticals (TELO), Coherus BioSciences (CHRS), Vaxart (VXRT), OptiNose (OPTN), Anixa Biosciences (ANIX), Adverum Biotechnologies (ADVM), Fate Therapeutics (FATE), Vor Biopharma (VOR), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Editas Medicine Telomir Pharmaceuticals Coherus BioSciences Vaxart OptiNose Anixa Biosciences Adverum Biotechnologies Fate Therapeutics Vor Biopharma Black Diamond Therapeutics Pulmatrix (NASDAQ:PULM) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has stronger earnings and valuation, PULM or EDIT? Pulmatrix has higher earnings, but lower revenue than Editas Medicine. Pulmatrix is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmatrix$7.81M2.52-$14.12M-$2.61-2.07Editas Medicine$32.31M2.64-$153.22M-$2.88-0.36 Does the MarketBeat Community believe in PULM or EDIT? Editas Medicine received 117 more outperform votes than Pulmatrix when rated by MarketBeat users. Likewise, 53.23% of users gave Editas Medicine an outperform vote while only 48.28% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformPulmatrixOutperform Votes19648.28% Underperform Votes21051.72% Editas MedicineOutperform Votes31353.23% Underperform Votes27546.77% Do analysts recommend PULM or EDIT? Editas Medicine has a consensus target price of $6.83, suggesting a potential upside of 563.43%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07 Does the media refer more to PULM or EDIT? In the previous week, Editas Medicine had 5 more articles in the media than Pulmatrix. MarketBeat recorded 6 mentions for Editas Medicine and 1 mentions for Pulmatrix. Editas Medicine's average media sentiment score of 0.71 beat Pulmatrix's score of 0.00 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulmatrix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PULM or EDIT? Pulmatrix has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Is PULM or EDIT more profitable? Pulmatrix has a net margin of -96.51% compared to Editas Medicine's net margin of -340.96%. Pulmatrix's return on equity of -45.97% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Pulmatrix-96.51% -45.97% -30.72% Editas Medicine -340.96%-80.13%-50.99% Do institutionals and insiders hold more shares of PULM or EDIT? 11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 1.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryEditas Medicine beats Pulmatrix on 13 of the 18 factors compared between the two stocks. Remove Ads Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.71M$6.35B$5.26B$7.12BDividend YieldN/A2.85%4.89%4.11%P/E Ratio-2.056.8621.4217.49Price / Sales2.52187.35355.0088.70Price / CashN/A65.6738.1834.64Price / Book1.105.576.233.79Net Income-$14.12M$141.89M$3.21B$247.56M7 Day Performance-24.90%-11.51%-8.47%-6.78%1 Month Performance-26.28%-16.37%-4.47%-10.82%1 Year Performance168.79%-17.85%2.76%-7.84% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.0526 of 5 stars$5.40-9.4%N/A+168.8%$19.71M$7.81M-2.0520News CoverageGap DownEDITEditas Medicine3.8941 of 5 stars$1.16-7.2%$6.83+489.1%-84.7%$96.25M$32.31M-0.45230TELOTelomir Pharmaceuticals1.3922 of 5 stars$3.23-18.2%$15.00+364.4%-58.1%$96.13MN/A-5.571High Trading VolumeCHRSCoherus BioSciences2.962 of 5 stars$0.81-3.8%$5.38+566.0%-67.8%$93.53M$266.96M-10.09330Gap DownVXRTVaxart2.6224 of 5 stars$0.41-2.7%$3.00+631.7%-68.8%$93.46M$28.70M-1.00120OPTNOptiNose2.6994 of 5 stars$9.17+0.2%$9.00-1.9%-54.0%$92.25M$78.23M-2.18190Positive NewsANIXAnixa Biosciences2.7264 of 5 stars$2.86-3.7%$9.00+214.7%-20.9%$92.08M$210,000.00-7.335ADVMAdverum Biotechnologies4.2023 of 5 stars$4.37-5.2%$27.83+536.9%-69.4%$90.91M$1M-0.73190News CoverageGap DownFATEFate Therapeutics3.5256 of 5 stars$0.79-7.0%$5.43+587.1%-89.1%$90.54M$13.63M-0.48550VORVor Biopharma1.5515 of 5 stars$0.72-4.4%$8.86+1,130.2%-73.7%$89.89MN/A-0.44140BDTXBlack Diamond Therapeutics2.4164 of 5 stars$1.55-3.7%$14.60+841.9%-72.3%$87.83MN/A-1.1790Gap Down Remove Ads Related Companies and Tools Related Companies Editas Medicine Alternatives Telomir Pharmaceuticals Alternatives Coherus BioSciences Alternatives Vaxart Alternatives OptiNose Alternatives Anixa Biosciences Alternatives Adverum Biotechnologies Alternatives Fate Therapeutics Alternatives Vor Biopharma Alternatives Black Diamond Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PULM) was last updated on 4/6/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PULM Stock Free PULM Stock Alerts